Global Celiac Disease Drug Market Size By Type (Distension, Diarrhea), By Application (First line of treatment, Second line of treatment), By Region, And Segment Forecasts, 2023 to 2032

The Global Celiac Disease Drug Market was valued at USD 740 million in 2023 and is projected to reach USD 2.1 billion by 2031, expanding at a CAGR of 13.9% during the forecast period from 2023 to 2031. The market is driven by increasing awareness of celiac disease, a rising number of diagnosed cases globally, and growing investments in the development of gluten-degrading enzyme therapies and immune-modulating drugs. Despite the current reliance on a strict gluten-free diet, there is growing demand for pharmacological solutions that can either complement or replace dietary management.

Drivers:

1. Rising Prevalence and Diagnosis Rates:

Celiac disease is becoming increasingly recognized as a global public health concern, with prevalence rates rising across developed and developing nations. Greater awareness and improved diagnostic tools are leading to higher diagnosis rates, thereby fueling demand for effective therapeutic options.

2. Advancement in Drug Development:

Research and development activities focusing on novel mechanisms—such as enzymatic therapies (glutenases), immune tolerance inducers, and zonulin antagonists—are expanding treatment possibilities beyond diet management.

3. Patient Dissatisfaction with Gluten-Free Diet (GFD):

Strict adherence to a gluten-free diet can be socially and economically burdensome. Many patients continue to experience symptoms despite following a GFD, increasing demand for adjunctive drug therapies.

Restraints:

1. Limited Commercial Approvals:

Currently, there are no FDA-approved drugs for the treatment of celiac disease. Most therapies remain in clinical or preclinical stages, limiting near-term market revenue potential.

2. Regulatory and Clinical Challenges:

Developing drugs that effectively target the pathophysiology of celiac disease without severe side effects remains a complex task. Regulatory hurdles further delay the availability of these therapies.

Opportunity:

1. Strong Pipeline and Investment Trends:

The pipeline of celiac disease drugs is robust, with several candidates in Phase II and III trials. Increased funding from both private and public sectors supports innovation and accelerates the path to commercial availability.

2. Expansion into Emerging Markets:

As awareness of autoimmune diseases grows in emerging economies, pharmaceutical companies have the opportunity to introduce celiac therapies alongside educational campaigns and diagnostics.

Market by System Type Insights:

By drug type, the Enzyme Therapy segment held the largest market share in 2023. Enzyme-based drugs, such as latiglutenase, are designed to break down gluten peptides in the digestive tract before they trigger an immune response. These drugs are gaining traction due to their potential to be taken alongside meals, offering a practical treatment option.

The Immune Modulator segment is expected to exhibit the highest growth rate during the forecast period, fueled by advancements in biologics and the rising interest in immunotherapy for autoimmune conditions.

Market by End-use Insights:

The Hospital Pharmacies segment led the market in 2023, accounting for over 40% of the revenue. These facilities remain critical in managing moderate-to-severe cases that require specialist consultation.

The Online Pharmacies segment is expected to grow at a notable pace due to increased digital health adoption and the convenience of home delivery for chronic condition medications.

Market by Regional Insights:

North America dominated the market in 2023 due to high awareness levels, advanced healthcare infrastructure, and substantial investment in R&D for autoimmune disease therapies.

Europe holds the second-largest share, driven by national-level screening programs and supportive regulatory frameworks.

The Asia-Pacific region is poised to be the fastest-growing market, benefiting from improving diagnostic rates and increasing healthcare spending.

Competitive Scenario:

Key players in the market include ImmunogenX, 9 Meters Biopharma, Takeda Pharmaceutical Company Limited, Cour Pharmaceutical Development Company, and Anokion SA. These firms are focusing on innovation in enzyme-based therapies, immune modulation, and zonulin antagonism.

Key developments:

In 2024, ImmunogenX initiated Phase III trials for latiglutenase in collaboration with Mayo Clinic.

In 2023, 9 Meters Biopharma expanded its R&D pipeline with a second-generation oral peptide for mucosal healing.

In 2025, Takeda Pharmaceutical announced a strategic partnership to co-develop celiac disease therapeutics targeting gut permeability.

Scope of Work – Global Celiac Disease Drug Market

Key Market Developments:

2023 – 9 Meters Biopharma secures FDA Fast Track designation for larazotide acetate.

2024 – Cour Pharmaceuticals announces positive Phase IIb results for its immune tolerance induction therapy.

2025 – Anokion receives Series C funding to advance its antigen-specific immune modulation approach for celiac disease.

FAQs:

1) What is the current market size of the Global Celiac Disease Drug Market?

The market size was valued at USD 740 million in 2023.

2) What is the major growth driver of the Global Celiac Disease Drug Market?

The rising global prevalence and diagnosis of celiac disease coupled with dissatisfaction with gluten-free diet therapies.

3) Which is the largest region during the forecast period in the Global Celiac Disease Drug Market?

North America is expected to remain the largest regional market due to advanced healthcare infrastructure and strong R&D activity.

4) Which segment accounted for the largest market share in Global Celiac Disease Drug Market?

The Enzyme Therapy segment led the market in 2023.

5) Who are the key market players in the Global Celiac Disease Drug Market?

Key players include ImmunogenX, 9 Meters Biopharma, Takeda, Cour Pharmaceuticals, and Anokion SA.